Movement Alert｜Sanofi SA Overnight Rise 3.18%, Q3 Dupixent Sales Growth Draws Market Focus

Market Focus10-30

On October 30, Sanofi SA recorded an Overnight rise of 3.18%, trading at $44.5 per share, with turnover of $192,100.

The move followed the company’s third-quarter update showing Dupixent sales of €5.7 billion, up 34.8% year over year, while vaccines sales were €3.2 billion, down 6.6%. The market appeared to focus more on the strong growth of the company’s key blockbuster product.

Before the release, consensus expectations had pointed to revenue growth of 2.57% and an EPS decline of 4.85%, indicating a relatively cautious setup for the quarter. Additional support for sentiment came from Sanofi SA’s recent letter of intent in Canada covering Dupixent in four additional indications, reinforcing expectations for further volume expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment